Urge your members of Congress to support continued medical research funding
The American Society of Hematology (ASH) leads the world in promoting and supporting clinical and scientific hematology research through its many innovative award programs, meetings, publications, and advocacy efforts.
Blood is the official journal of the American Society of Hematology and the most cited peer-reviewed publication in the field. It is published weekly every Thursday, except for the last week in December, in addition to the ASH Annual Meeting Abstracts issue in November.
Explore programs offered by ASH to support clinical and scientific hematology research
ASH's strategic plan highlighting the importance of placing hematology as a top funding priority in the healthcare community
Dr. Raje reviews a study that compares daratumumab, lenalidomide, and dexamethasone with lenalidomide and dexamethasone alone for the treatment of patients with multiple myeloma who have received one prior line of therapy.
Dr. Coetzer discusses a study that looks at a therapeutic genome editing strategy where a benign naturally occurring mutation is repeated ex vivo in cells from SCD patients.
Dr. Abdel-Wahab and Dr. Taylor study the biology of mutant IDH1 in a myeloid-specific context with the additive effect of aging, and highlight one of the TET2-independent consequences of 2HG.
Dr. Keel discusses studies carried out to determine the efficacy of androgens to treat or prevent other disease manifestations associated with short telomere syndromes.
The Centers for Medicare and Medicaid Services (CMS) released the annual set of proposals governing payments for services provided to patients admitted to the hospital, commonly referred to as the hospital inpatient prospective payment system (IPPS). ASH explores how this will affect hematologists.
As part of the American Society of Hematology’s (ASH)
multifaceted initiative to address the burden of sickle cell disease, ASH is in
the process of working with stakeholders to improve access to care for
individuals with sickle cell disease.
Included in this effort is
On March 8, 2016, the Center for Medicare and Medicaid Services (CMS) proposed a new experiment in payment rates for physician-administered drugs such as chemotherapy. This plan would change the current formula for drug payment so that payments for expensive drugs are reduced in certain areas of the country. In a second phase, CMS would be able to adopt certain tools to further adjust pricing for drugs.
ASH submitted comments to the National Heart, Lung and Blood Institute (NHLBI) on its recently released draft strategic research priorities that will inform the Institute’s policy and funding decisions for the next several years. ASH’s comments were developed based on the ASH Agenda for Hematology Research and input from members of the ASH Committee on Scientific Affairs and ASH Scientific Committees.
Urge your members of Congress to support continued medical research funding.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology